Table 3 Antithrombotic Treatment at Discharge.

From: Comparison of Systematic Ticagrelor-Based Dual Antiplatelet Therapy to Selective Triple Antithrombotic Therapy for Left Ventricle Dysfunction Following Anterior STEMI

 

CHUM (Selective TATT) N = 66*

CHUS (Ticagrelor-DAPT) N = 101*

Unadjusted p-value

DAPT

37 (56%)

94 (93%)

<0.0001

  Clopidogrel

15 (41%)

7 (7%)

<0.0001

  Ticagrelor

13 (35%)

85 (90%)

<0.0001

  Prasugrel

9 (24%)

2 (2%)

0.0002

TATT

29 (44%)

7 (7%)

<0.0001

  Clopidogrel

24 (83%)

6 (86%)

1.0000

  Ticagrelor

1 (3%)

1 (14%)

0.3556

  Prasugrel

4 (14%)

0 (0%)

0.5658

  VKA

29 (100%)

7 (100%)

—

  NOAC

0 (0%)

0 (0%)

 
  1. *Three CHUM patients and 7 CHUS patients died prior to discharge.
  2. VKA: Vitamin K antagonist; NOAC: Non-vitamin K antagonist oral anticoagulant.
Back to article page